Acarix ABACIXF 44 Cyclically Adjusted PB Ratio is 0.24 as of Jul. 03, 2026, which is 4% below its 10-year median of 0.25. GuruFocus rates ACIXF with a GF Score™ of 44/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 525 Medical Devices & Instruments companies, Acarix AB ranks better than 92% on this metric.
The historical rank and industry rank for Acarix AB's Cyclically Adjusted PB Ratio or its related term are showing as below:
ACIXF'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.21 Med: 0.25 Max: 0.36
Current: 0.24
During the past years, Acarix AB's highest Cyclically Adjusted PB Ratio was 0.36. The lowest was 0.21. And the median was 0.25.
ACIXF's Cyclically Adjusted PB Ratio is ranked better than 92% of 525
companies
in the Medical Devices & Instruments industry
Industry Median: 1.79
vs ACIXF: 0.24
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Acarix AB's adjusted book value per share data for the three months ended in Mar. 2026 was $0.003. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.12 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Acarix AB (OTCPK:ACIXF) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Acarix AB Cyclically Adjusted PB Ratio Related Terms
Acarix AB Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Acarix AB's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACIXF vs ABT, SYK, MDT: Cyclically Adjusted PB Ratio Comparison
For the Medical Devices subindustry, Acarix AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acarix AB Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Acarix AB's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Acarix AB's Cyclically Adjusted PB Ratio falls into.
Acarix AB Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Acarix AB's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 0.24 mean?
Acarix AB (ACIXF) has a Cyclically Adjusted PB Ratio of 0.24 as of Jul. 03, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Acarix AB and its competitors. This is near median its historical median of 0.25. Over the past decade, Acarix AB's Cyclically Adjusted PB Ratio has ranged from 0.21 to 0.36. According to the industry distribution chart, Acarix AB ranks #42 out of 525 companies in the Medical Devices & Instruments industry, placing it in the top 8%.
Is Acarix AB's Cyclically Adjusted PB Ratio too high?
Acarix AB's current Cyclically Adjusted PB Ratio of 0.24 is near median its 10-year median of 0.25. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 0.36. The Medical Devices & Instruments industry median Cyclically Adjusted PB Ratio is 1.79. Acarix AB's value of 0.24 is 86.6% below this industry median. Based on the distribution chart, Acarix AB ranks #42 out of 525 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Acarix AB has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's Cyclically Adjusted PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Acarix AB ranks #42 out of 525 companies for Cyclically Adjusted PB Ratio. This places Acarix AB in the top 8% of its industry — outperforming the majority of peers. The industry median Cyclically Adjusted PB Ratio is 1.79. Acarix AB's value of 0.24 is 86.6% below this benchmark. Historically, Acarix AB's own Cyclically Adjusted PB Ratio has ranged from 0.21 to 0.36 over the past decade. While the company's 10-year median is 0.25 vs. the industry median of 1.79, Acarix AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PB Ratio among Medical Devices & Instruments companies is 1.79, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acarix AB's current Cyclically Adjusted PB Ratio of 0.24 is 86.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Acarix AB and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PB Ratio is 1.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acarix AB's current Cyclically Adjusted PB Ratio is 0.24, which is near median its own 10-year median of 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Based on GuruFocus' analysis, Acarix AB (ACIXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 44.4% above its estimated fair value. The current Cyclically Adjusted PB Ratio is 0.24, which is near median its 10-year median of 0.25 and 86.6% below the Medical Devices & Instruments industry median of 1.79. Acarix AB's overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Acarix AB (ACIXF), the current Cyclically Adjusted PB Ratio is 0.24 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acarix AB (ACIXF) Overvalued in 2026?
Based on GuruFocus' analysis, Acarix AB stock appears to be overvalued.
The current stock price of $0.03 is trading 44.4% above its estimated GF Value™ of $0.02.
GuruFocus considers Acarix AB to be Significantly Overvalued.
Key valuation signals for ACIXF:
Cyclically Adjusted PB Ratio: 0.24 (near median its 10-year median of 0.25)
GF Value™: $0.02 vs. price of $0.03 (44.4% above fair value)
Industry Position: 86.6% below the Medical Devices & Instruments median (#42 of 525)
No single metric tells the full story. See the ACIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
44GF Score
Get the complete analysis for ACIXF
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACIXF has been successfully added to your 
